Search

Displaying results 701 - 710 of 4207 in total
  1. Drug

    Autologous peripheral blood-derived CD34+ cells

    go.drugbank.com/drugs/DB16367
    ApprovedInvestigational

    Autologous peripheral blood-derived CD34+ cells, or CLBS119 (a proprietary version being developed by Caladrius Biosciences, Inc.), are hematopoietic stem cells. … [L27741] It is also a cell therapy being investigated by Caladrius Biosciences in the clinical trial NCT04522817 (CLBS119 for Repair of COVID-19 Induced Pulmonary Damage).

  2. Drug

    Quinupristin

    go.drugbank.com/drugs/DB01369
    Approved

    Quinupristin/dalfopristin is a combination of two antibiotics used to treat infections by staphylococci and by vancomycin-resistant Enterococcus faecium.

  3. Drug

    Oxilofrine

    go.drugbank.com/drugs/DB11610
    Approved

    It is currently marketed in Canada by Valeant under the tradename Cophylac.

  4. Drug

    Cefiderocol

    go.drugbank.com/drugs/DB14879
    ApprovedInvestigational

    Cefiderocol was granted designation as a Qualified Infectious Disease Product and granted priority review status by the FDA on November 14, 2019. … [FDA Label] This indication was supported by a positive clinical trial composed of 448 patients with complicated urinary tract infections which demonstrated a 72.6% rate of symptom resolution and bacterial

  5. Drug

    Trastuzumab

    go.drugbank.com/drugs/DB00072
    ApprovedInvestigational

    In November 2023, trastuzumab was also approved by the EMA under the brand name Herwenda.[L49339] … Kanjinti (trastuzumab-anns)[L14135] and Hercessi[L52840] are other biosimilars approved by the FDA. In Canada, biosimilars ONTRUZANT[[L40303, L40308] and Adheroza[L52835] are approved.

  6. Drug

    Dichlorobenzyl alcohol

    go.drugbank.com/drugs/DB13269
    Approved

    [L1113] On the other hand, dichlorobenzyl alcohol is categorized by the FDA in the inactive ingredient for approved drug products.[L2773] … [A33047] Dichlorobenzyl alcohol is considered as an active ingredient found in several marketed OTC products by Health Canada which has categorized this agent as an anatomical therapeutic chemical.

  7. Drug

    Glycyrrhizic acid

    go.drugbank.com/drugs/DB13751
    ApprovedInvestigational

    [F80] It was approved by Health Canada to be used in over-the-counter products but all the products are currently on the status canceled post marketed.[L1113] … [A33062] From January 2014, glycyrrhizic acid as part of the licorice extract was approved by the FDA as an existing food sweetener.

  8. Drug

    Cilastatin

    go.drugbank.com/drugs/DB01597
    ApprovedInvestigational

    The first combination product containing both drugs was approved by the FDA in November of 1985 under the trade name Primaxin, marketed by Merck & Co. … Since the antibiotic, [imipenem], is one such antibiotic that is hydrolyzed by dehydropeptidase, cilastatin is used in combination with imipenem to prevent its metabolism.

  9. Drug

    Seproxetine

    go.drugbank.com/drugs/DB06731
    Experimental

    Seproxetine was being investigated by Eli Lilly as an antidepressant but development was never completed and the drug was never marketed.

  10. Drug

    Cerliponase alfa

    go.drugbank.com/drugs/DB13173
    ApprovedInvestigational

    [L51339] It was also approved by the EMA on May 30, 2017 [L51324] and by Health Canada on December 19, 2018. … [L51319] On April 27, 2017, cerliponase alfa was first approved by the FDA as the first treatment for neuronal ceroid lipofuscinosis type 2 (CLN2), also known as TPP1 deficiency.